牛皮和现型年龄加速与美国成年人所有原因和心血管疾病死亡风险相关
Wen-Qi Zhao1,2,3, Rui Gao4, Jian-Yong Fan3
1Department of Dermotology, Ningxia Medical University, Yinchuan, China.
European journal of medical research
|September 30, 2025
概括
通过表型年龄加速 (PhenoAge-accel) 测量的加速生物衰老,增加了牛皮的风险. 牛皮和PhenoAge-accel的组合显著增加了所有原因和心血管疾病死亡率的风险.
科学领域:
- 老年学是一门学科.
- 皮肤病学 皮肤病学
- 心脏病学 心脏病学
背景情况:
- 牛皮是一种慢性炎症性皮肤疾病,与心血管疾病 (CVD) 风险增加有关.
- 现型年龄加速 (PhenoAge-accel) 测量了与时间年龄相对的生物衰老.
- 牛皮和生物衰老都相互关联,影响疾病的发病和进展.
研究的目的:
- 为了检查PhenoAge-accel和牛皮风险之间的关联.
- 调查牛皮和PhenoAge-accel对所有原因和心血管疾病死亡率的联合影响.
主要方法:
- 利用了来自全国健康和营养检查调查 (NHANES) 的11,443名参与者的数据.
- 使用后勤回归来评估PhenoAge-accel与牛皮的关联.
- 应用了考克斯的比例危险模型来评估对死亡风险的联合影响.
主要成果:
- Age-accel与牛皮风险 (OR=1.83) 有积极的关联.
- 在平均10.91年的随访期间,死亡人数为1059人 (306人死于心血管疾病).
- 牛皮和PhenoAge-accel一起显著增加了全因死亡率 (HR=2.70) 和心血管疾病死亡风险.
结论:
- Age-accel是患上牛皮的重要危险因素.
- 患有牛皮和PhenoAge-accel的个体面临着显著更高的全因和心血管疾病死亡风险.
相关概念视频
Psychoneuroimmunology: Cardiovascular Disease
402
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
402
Coronary Artery Disease I: Introduction
882
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
882
Pharmacodynamics in Geriatric Patients: Effects of Age
188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188
Atherosclerosis I: Introduction
923
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
923
Longitudinal Research
13.1K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.1K
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321


